Harvard, Dana-Farber License Screening Platform to Acetylon | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.

The partners did not provide details on the screening and optimization platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.